1. Ramakrishnan VT, Cattamanchi S. Transfusion practices in trauma. Indian J Anaesth 2014; 58(5): 609-15. doi:
10.4103/0019-5049.144668.
2. Shaz BH, Dente CJ, Harris RS, MacLeod JB, Hillyer CD. Transfusion management of trauma patients. Anesth Analg
2009; 108(6): 1760-8. doi: 10.1213/ane.0b013e3181a0b6c6.
3. Evanovitch D. A primer in pretransfusion testing. Transfus Apher Sci 2012; 46(3): 281-6. doi: 10.1016/j. transci.2012.03.017.
4. Milkins C, Berryman J, Cantwell C, Elliott C, Haggas R, Jones J, et al. Guidelines for pre-transfusion compatibility
procedures in blood transfusion laboratories. British Committee for Standards in Haematology. Transfus Med
2013; 23(1): 3-35. doi: 10.1111/j.1365-3148.2012.01199.x.
5. Shulman IA, Downes KA, Sazama K, Maffei LM. Pretransfusion compatibility testing for red blood cell administration. Curr Opin Hematol 2001; 8(6): 397-404. doi: 10.1097/00062752-200111000-00014.
6. Oberman HA. The present and future crossmatch.Transfusion 1992; 32(9): 794-6.
7. White J. Pre-transfusion testing. ISBT Sci Ser 2009; 4(1): 37-44. doi: 10.1111/j.1751-2824.2009.01211.x.
8. Beck ML, Tilzer LL. Red cell compatibility testing: a perspective for the future. Transfus Med Rev 1996; 10(2):
118-30. doi: 10.1016/s0887-7963(96)80088-5.
9. Schmidt P. Standards for Blood Banks and Transfusion Services. 11th ed. Bethesda: American Association of Blood
Banks; 1984.
10. Food and Drug Administration (FDA). Guidance for Industry “Computer Crossmatch” (Computerized Analysis
of the Compatibility between the Donor’s Cell Type and the Recipient’s Serum or Plasma Type); 2011. Available from:
https://www.fda.gov/media/80857/download
11. Powers A, Chandrashekar S, Mohammed M, Uhl L. Identification and evaluation of false-negative
antibody screens. Transfusion 2010; 50(3): 617-21. doi:10.1111/j.1537-2995.2009.02464.x.
12. Orlando N, Bianchi M, Valentini CG, Maresca M, Massini G, Putzulu R, et al. Red cell alloantibody screening:
comparative analysis of three different technologies. Transfus Med Hemother 2018; 45(3): 179-83. doi:
10.1159/000484570.
13. Garratty G. How concerned should we be about missing antibodies to low incidence antigens? Transfusion 2003;
43(7): 844-7. doi: 10.1046/j.1537-2995.2003.00492.x.
14. Lange J, Selleng K, Heddle NM, Traore A, Greinacher A. Coombs’ crossmatch after negative antibody screening--a
retrospective observational study comparing the tube test and the microcolumn technology. Vox Sang 2010; 98(3 Pt
1): e269-75. doi: 10.1111/j.1423-0410.2009.01278.x.
15. Narvios AB, Rozner M, Lichtiger B. Thirty-day typing and screening for patients undergoing elective surgery:
experience at a large cancer center. Transfusion 2006; 46(3):348-51. doi: 10.1111/j.1537-2995.2006.00728.x.
16. Knowles SM, Milkins CE, Chapman JF, Scott M. The United Kingdom National External Quality Assessment
Scheme (blood transfusion laboratory practice): trends in proficiency and practice between 1985 and 2000.
Transfus Med 2002; 12(1): 11-23. doi: 10.1046/j.1365-3148.2002.00353.x.
17. Downes KA, Shulman IA. Pretransfusion testing practices in North America, 2005-2010: an analysis of the College
of American Pathologists Interlaboratory Comparison Program J-survey data, 2005-2010. Arch Pathol Lab Med
2012; 136(3): 294-300. doi: 10.5858/2011-0127-cpr.1.
18. Devbhandari MP, Farid S, Goatman C, Moussa Y, Rammohan KS, Krysiak P, et al. Is type and screen only policy safe for patients undergoing elective lobectomy? Eur J Cardiothorac Surg 2013; 44(6): 1113-6. doi: 10.1093/ejcts/
ezt209.
19. Pei Z, Szallasi A. Prevention of surgical delays by preadmission type and screen in patients with scheduled surgical procedures: improved efficiency. Blood Transfus
2015; 13(2): 310-2. doi: 10.2450/2014.0172-14.
20. Kuriyan M, Fox E. Pretransfusion testing without serologic crossmatch: approaches to ensure patient safety. Vox Sang 2000; 78(2): 113-8. doi: 10.1159/000031160.
21. Tiwari AK, Aggarwal G, Dara RC, Arora D, Gupta GK,Raina V. First Indian study to establish safety of immediatespin crossmatch for red blood cell transfusion in antibody screen-negative recipients. Asian J Transfus Sci 2017; 11(1):
40-4. doi: 10.4103/0973-6247.200774.
22. Setia R, Sachdeva P, Arora S, Handoo A, Kapoor M. Making type and screen policy an essential component
of pretransfusion testing: need of the hour in India. Glob J Transfus Med 2017; 2(1): 34-7. doi: 10.4103/gjtm.gjtm_2_17.
23. Chaudhary R, Agarwal N. Safety of type and screen method compared to conventional antiglobulin crossmatch
procedures for compatibility testing in Indian setting. Asian J Transfus Sci 2011; 5(2): 157-9. doi: 10.4103/0973-
6247.83243.
24. Agrawal A. Type and screen policy: is there any compromise on blood safety? Transfus Apher Sci 2014; 50(2): 271-3. doi:10.1016/j.transci.2014.01.003.
25. Pathak S, Chandrashekhar M, Wankhede GR. Type and screen policy in the blood bank: is AHG cross-match still
required? a study at a multispecialty corporate hospital in India. Asian J Transfus Sci 2011; 5(2): 153-6. doi:
10.4103/0973-6247.83242.
26. Hasan O, Khan EK, Ali M, Sheikh S, Fatima A, Rashid HU. “It’s a precious gift, not to waste”: is routine cross matching
necessary in orthopedics surgery? retrospective study of 699 patients in 9 different procedures. BMC Health Serv
Res 2018; 18(1): 804. doi: 10.1186/s12913-018-3613-9.
27. Zewdie K, Genetu A, Mekonnen Y, Worku T, Sahlu A, Gulilalt D. Efficiency of blood utilization in elective surgical
patients. BMC Health Serv Res 2019; 19(1): 804. doi:10.1186/s12913-019-4584-1.
28. Hall TC, Pattenden C, Hollobone C, Pollard C, Dennison AR. Blood transfusion policies in elective general surgery:
how to optimise cross-match-to-transfusion ratios. Transfus Med Hemother 2013; 40(1): 27-31. doi: 10.1159/000345660.
29. Alavi-Moghaddam M, Bardeh M, Alimohammadi H, Emami H, Hosseini-Zijoud SM. Blood transfusion practice
before and after implementation of type and screen protocol in emergency department of a university affiliated
hospital in Iran. Emerg Med Int 2014; 2014: 316463. doi:10.1155/2014/316463.
30. Shulman IA, Nelson JM, Kent DR, Jacobs VL, Nakayama RK, Malone SA. Experience with a cost-effective crossmatch
protocol. JAMA 1985; 254(1): 93-5.
31. Aggarwal G, Tiwari AK, Arora D, Dara RC, Acharya DP, Bhardwaj G, et al. Advantages of type and screen policy:
perspective from a developing country! Asian J Transfus Sci 2018; 12(1): 42-5. doi: 10.4103/ajts.AJTS_31_17.
32. Alghamdi S, Gonzalez B, Howard L, Zeichner S, LaPietra A, Rosen G, et al. Reducing blood utilization by
implementation of a type-and-screen transfusion policy a single-institution experience. Am J Clin Pathol 2014;
141(6): 892-5. doi: 10.1309/ajcpx69venskotyw.
33. Patten E, Alperin JB. Type and screen: a safe and effective preoperative blood ordering policy with emphasis on its use in obstetrics and gynecology. Am J Obstet Gynecol 1982;142(5): 563-7. doi: 10.1016/0002-9378(82)90762-1.